ChemicalBook > CAS DataBase List > CUDC-101

CUDC-101

CUDC-101 Structure
CUDC-101
  • CAS No.1012054-59-9
  • Chemical Name:CUDC-101
  • CBNumber:CB12500941
  • Molecular Formula:C24H26N4O4
  • Formula Weight:434.49
  • MOL File:1012054-59-9.mol
CUDC-101 Property
  • Melting point 174-177℃
  • Density 1.28
  • storage temp. -20°C
  • solubility DMSO: soluble
  • pka 9.47±0.20(Predicted)
  • form solid
  • color White or off-white
  • Stability Stable for 1 year from date of purchase as supplied. Solutions in DMSO may be stored at -20°C for up to 1 month.
  • InChIKey PLIVFNIUGLLCEK-UHFFFAOYSA-N
  • FDA UNII 1A7Y9MP123
  • UNSPSC Code 12352200
  • NACRES NA.41
Safety
  • WGK Germany  :3
Hazard and Precautionary Statements (GHS)
  • Symbol(GHS)
  • Signal wordWarning
  • Hazard statements H315-H319-H335
  • Precautionary statements P280-P305+P351+P338
CUDC-101 Price More Price(2)
  • Brand: Sigma-Aldrich(India)
  • Product number: EPS003
  • Product name : CUDC 101
  • Purity: A potent inhibitor of HDACs and receptor tyrosine kinases
  • Packaging: 5MG
  • Price: ₹19095.3
  • Updated: 2022/06/14
  • Buy: Buy
  • Brand: Sigma-Aldrich(India)
  • Product number: EPS003
  • Product name : CUDC 101
  • Purity: A potent inhibitor of HDACs and receptor tyrosine kinases
  • Packaging: 25MG
  • Price: ₹71445
  • Updated: 2022/06/14
  • Buy: Buy

CUDC-101 Chemical Properties,Usage,Production

  • Description CUDC-101 (1012054-59-9) is a novel hybrid dual-acting HDAC and receptor tyrosine kinase inhibitor. It is a potent HDAC inhibitor which also inhibits EGFR and HER2,? IC50?= 4.4, 2.4 and 15.7 nM respectively.1?It not only blocks EGFR and HER2 but also attenuates multiple compensatory pathways such as AKT, HER3 and MET which enable tumor cells to escape the effects of conventional EGFR/HER2 inhibitors.1,2
  • Uses CUDC-101 is a potent multi-acting HDAC (histone deacetylase), EGFR (epidermal growth factor receptor), and HER2 ( human epidermal growth factor receptor 2) inhibitor for the treatment of cancer.
  • Uses Inhibitor of HDAC, EGFR, and HER2 with an IC50 of 4.4, 2.4, and 15.7 nM, respectively.
  • General Description A potent multitargeted inhibitor of histone deacetylase (HDAC) and the receptor kinases epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2), with IC50 values of 4.4, 2.4, and 15.7 nM, respectively.

    Displays potent antiproliferative and proapoptotic activities against cultured and implanted tumor cells that are sensitive or resistant to several approved single-targeted drugs.
  • in vivo

    CUDC-101 (120 mg/kg, iv, daily) induces tumor regression in the Hep-G2 liver cancer model and is more efficacious than erlotinib at its maximum tolerated dose (MTD). In the erlotinib-resistant A549 NSCLC xenograft model, CUDC-101 (120 mg/kg) shows potent inhibition of tumor growth. In the erlotinib-sensitive H358 NSCLC models, CUDC-101 (15, 30, 60 mg/kg, i.v.) inhibits tumor growth in a dose-dependent manner. CUDC-101 (120 mg/kg) causes significant tumor regression in the lapatinib-resistant, HER2-negative, EGFR-overexpressing MDA-MB-468 breast cancer model and the EGFR-overexpressing CAL-27 head and neck squamous cell carcinoma (HNSCC) model. CUDC-101 (120 mg/kg) also inhibits tumor growth in the K-ras mutant HCT116 colorectal and EGFR/HER2 (neu)-expressing HPAC pancreatic cancer models[1].
    In an in vivo mouse model of metastatic ATC, CUDC-101 inhibits tumor growth and metastases, and significantly prolongs survival[3].
    CUDC-101 (120 mg/kg) is effective against a broad range of tumor types in xenograft models[4].

  • target EGFR
  • IC 50 EGFR: 2.4 nM (IC50); HER2: 15.7 nM (IC50); HDAC: 4.4 nM (IC50); HDAC1: 4.5 nM (IC50); HDAC2: 12.6 nM (IC50); HDAC3: 9.1 nM (IC50); HDAC4: 13.2 nM (IC50); HDAC6: 5.1 nM (IC50); HDAC5: 11.4 nM (IC50); HDAC9: 67.2 nM (IC50); HDAC10: 26.1 nM (IC50); HDAC8: 79.8 nM (IC50); HDAC7: 373 nM (IC50)
  • References 1) Lai?et al. (2010),?CUDC-101, a multitargeted inhibitor of histone deacetylase, epidermal growth factor receptor, and human epidermal growth factor receptor 2, exerts potential anticancer activity; Cancer Res.,?70?3647 2) Cai?et al.?(2010), Discovery of 7-(4-(3-ethynylphenylamino)-7-methoxyquinazolin-6-yloxy)-N-hydroxyheptanamide (CUDc-101) as a potent multi-acting HDAC, EGFR, and HER2 inhibitor for the treatment of cancer; J. Med. Chem.,?53?2000
CUDC-101 Preparation Products And Raw materials
Raw materials
Preparation Products
CUDC-101 Suppliers
Global(141)Suppliers
  • Supplier：
    Capot Chemical Co.,Ltd.
  • Tel：+86-（0）57185586718<br/>+86-13336195806
  • Email：sales@capot.com
  • Country：China
  • ProdList：29730
  • Advantage：60
  • Supplier：
    Biochempartner
  • Tel：0086-13720134139
  • Email：candy@biochempartner.com
  • Country：CHINA
  • ProdList：965
  • Advantage：58
  • Supplier：
    TargetMol Chemicals Inc.
  • Tel： +17819995354
  • Email：marketing@targetmol.com
  • Country：United States
  • ProdList：32281
  • Advantage：58
  • Supplier：
    InvivoChem
  • Tel：+1-708-310-1919<br/>+1-13798911105
  • Email：sales@invivochem.cn
  • Country：United States
  • ProdList：6391
  • Advantage：58
CUDC-101 Spectrum
1012054-59-9, CUDC-101Related Search:
  • Inhibitors
  • Antineoplastic
  • Inhibitor
  • 抑制剂
  • 信号转导通路激酶抑制剂
  • 生物试剂
  • 合成有机化合物配体
  • 细胞生物学试剂
  • 小分子抑制剂，天然产物
  • 表观遗传学
  • CUDC-101(CUDC101) |CAS 1012054-59-9
  • 化合物CUDC-101,10 MM DMSO 溶液
  • CUDC-101,HDAC,EGFR和HER2抑制剂
  • 7-[[4-(3-炔基苯基氨基)-7-甲氧基喹唑啉-6-基]氧基]-N-羟基庚酰胺
  • HDAC、EGFR和HER2抑制剂(CUDC-101)
  • 化合物CUDC-101
  • 7-[[4-(3-乙炔基苯基氨基)-7-甲氧基喹唑啉-6-基]氧基]-N-羟基庚酰胺
  • 1012054-59-9
  • CUDC-101, 10 mM in DMSO
  • CURIS
  • CUDC101;CUDC 101
  • CS-330
  • CUDC101; CUDC 101; CUDC-101.
  • CUDC-101, >=98%
  • 7-[4-(3-ethynylanilino)-7-methoxyquinazolin-6-yl]oxy-N-hydroxyheptanamide
  • 7-[[4-(3-Ethynylphenylamino)-7-methoxyquinazolin-6-yl]oxy]-N-hydroxyheptanamide CUDC-101
  • 7-[[4-[(3-Ethynylphenyl)aMino]-7-Methoxy-6-quinazolinyl]oxy]-N-hydroxyheptanaMide
  • HeptanaMide, 7-[[4-[(3-ethynylphenyl)aMino]-7-Methoxy-6-quinazolinyl]oxy]-N-hydroxy-
  • 7-[[4-(3-Ethynylphenylamino)-7-methoxyquinazolin-6-yl]oxy]-N-hydroxyheptanamide
  • CUDC-101
  • CUDC101

Home

My